Clever Culture Systems (ASX:CC5) secured two new pharmaceutical orders, including an agreement for a paid evaluation of its APAS Independence imaging instrument with a new pharmaceutical customer, according to a Thursday filing with the Australian bourse.

The agreement includes an upfront payment covering installation, which is expected in June, and a non-refundable prepayment for a potential purchase following the evaluation, the company said.

The second purchase order is from a new single-site US customer. The instrument under the second order has been shipped and is also due to be installed in June.

Clever Culture said the volume of active global top-20 pharma customers deploying APAS increased in fiscal year 2026 and is expected to grow further in fiscal year 2027.